Read Our Investor Brief on Elanco Animal Health

Shares of Health Care sector company Elanco Animal Health moved -1.2% Friday, and are now trading at a price of $11.99. The mid-cap stock's daily volume was 5,629,798 compared to its average volume of 7,246,412. The S&P 500 index returned a 1.0% performance.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. The company is based in Greenfield and has 9,000 full time employees. Its market capitalization is $5,905,674,752.

7 analysts are following Elanco Animal Health and have set target prices ranging from $8.5 to $19.0 per share. On average, they have given the company a rating of hold. At today's prices, ELAN is trading -9.24% away from its average analyst target price of $13.21 per share.

The stock's 52 week high is $20.46 per share and its 52 week low is $7.88. With average free cash flows of $479.5 Million that have been growing at an average rate of 10.9% over the last 4 years, Elanco Animal Health declining stock performance may not be reflective of the quality of its underlying business.

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cashflow ($ k) YoY Growth (%)
2023-03-01 452,000 -184,000 636,000 -4.07
2022-02-28 483,000 -180,000 663,000 234.85
2021-03-01 -41,000 -239,000 198,000 -52.97
2020-02-28 224,000 -197,000 421,000 n/a
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS